Peter KolchinskyDirector · 10% owner
Capital Healthcare Fund LP RADirector · 10% owner
L.P. RA Capital ManagementDirector · 10% owner
L.P. RA Capital Nexus Fund IIIDirector
Rajeev M. ShahDirector · 10% owner
4
Filed Nov 3, 2026Period of report Oct 30, 20260001231919-26-001533
| Transaction | Security | Shares | Price | ValueValue (shares × price) | Held after | Ownership |
|---|---|---|---|---|---|---|
PurchaseNov 2, 2026 | Common StockF2F3 | 2,335,109 | $16.00 | $37.36M | 5,933,787 | IndirectSee footnotes |
PurchaseNov 2, 2026 | Common StockF2F6 | 164,891 | $16.00 | $2.64M | 1,495,971 | IndirectSee footnotes |
PurchaseOct 30, 2026 | Common StockF1F2F3 | 189,909 | $14.23 | $2.70M | 189,909 | IndirectSee footnotes |
PurchaseOct 30, 2026 | Common StockF4F2F3 | 263,911 | $14.92 | $3.94M | 453,820 | IndirectSee footnotes |
Filing footnotes · 6
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.61 to $14.58 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
- F3Held directly by the Fund.
- F4The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.65 to $15.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F5All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.
- F6Held directly by the Nexus Fund III.